Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyRopivacaine
Targets (1)
Enzymes (4)
Identification
- Name
- Ropivacaine
- Accession Number
- DB00296 (APRD00492)
- Type
- Small Molecule
- Groups
- Approved
- Description
Ropivacaine is a local anaesthetic drug belonging to the amino amide group. The name ropivacaine refers to both the racemate and the marketed S-enantiomer. Ropivacaine hydrochloride is commonly marketed by AstraZeneca under the trade name Naropin.
- Structure
Structure for DB00296 (Ropivacaine)
- Synonyms
- (S)-(−)-1-propyl-2',6'-pipecoloxylidide
- (S)-ropivacaine
- L-N-n-propylpipecolic acid-2,6-xylidide
- Ropivacaina
- Ropivacaine
- Ropivacainum
- External IDs
- Not Available
- Product Ingredients
Ingredient UNII CAS InChI Key Ropivacaine hydrochloride V910P86109 132112-35-7 VSHFRHVKMYGBJL-CKUXDGONSA-N Ropivacaine hydrochloride monohydrate Not Available Not Available Not applicable - Approved Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Naropin Injection, solution 2 mg/mL Epidural; Infiltration Fresenius Kabi 2009-08-04 Not applicable US 
Naropin Solution 5 mg Epidural; Infiltration Aspen Pharmacare Canada Inc. 1997-04-30 Not applicable Canada 
Naropin Solution 2 mg Epidural Aspen Pharmacare Canada Inc. 1997-04-30 Not applicable Canada Naropin Injection, solution 10 mg/mL Epidural Fresenius Kabi 2009-08-04 Not applicable US Naropin Solution 10 mg Epidural; Infiltration Aspen Pharmacare Canada Inc. 1997-04-30 Not applicable Canada Naropin Injection, solution 5 mg/mL Epidural; Infiltration; Perineural APP Pharmaceuticals, Inc. 2009-08-04 Not applicable US Naropin Injection, solution 5 mg/mL Epidural; Infiltration; Perineural General Injectables & Vaccines 2014-03-11 Not applicable US Naropin Injection, solution 7.5 mg/mL Epidural; Perineural Fresenius Kabi 2011-05-31 Not applicable US Naropin Inj 7.5mg/ml Liquid 7.5 mg Parenteral Astra Zeneca 1997-04-30 2003-11-18 Canada Ropivacaine Hydrochloride Injection Solution 2 mg Epidural; Infiltration Teva Not applicable Not applicable Canada Ropivacaine Hydrochloride Injection USP Solution 10 mg Epidural; Infiltration Hospira, Inc. 2010-12-14 Not applicable Canada Ropivacaine Hydrochloride Injection USP Solution 5 mg Epidural; Infiltration Hospira, Inc. 2010-12-14 Not applicable Canada Ropivacaine Hydrochloride Injection, USP Solution 7.5 mg Epidural Fresenius Kabi Not applicable Not applicable Canada Ropivacaine Hydrochloride Injection, USP Solution 2 mg Epidural; Infiltration Fresenius Kabi Not applicable Not applicable Canada Ropivacaine Hydrochloride Injection, USP Solution 10 mg Epidural Fresenius Kabi Not applicable Not applicable Canada Ropivacaine Hydrochloride Injection, USP Solution 2 mg Infiltration Hospira, Inc. Not applicable Not applicable Canada Ropivacaine Hydrochloride Injection, USP Solution 5 mg Epidural; Infiltration Fresenius Kabi Not applicable Not applicable Canada - Approved Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Ropivacaine Hydrochloride Injection, solution 5 mg/mL Parenteral Sandoz 2014-07-24 Not applicable US Ropivacaine Hydrochloride Injection, solution 5 mg/mL Epidural; Infiltration; Perineural Hospira, Inc. 2014-09-23 Not applicable US Ropivacaine Hydrochloride Injection, solution 2 mg/mL Epidural; Infiltration; Perineural Auro Medics Pharma Llc 2016-09-15 Not applicable US Ropivacaine Hydrochloride Injection, solution 2 mg/mL Epidural; Infiltration; Perineural Auro Medics Pharma Llc 2016-09-15 Not applicable US Ropivacaine Hydrochloride Injection, solution 7.5 mg/mL Epidural; Perineural Auro Medics Pharma Llc 2016-09-15 Not applicable US Ropivacaine Hydrochloride Injection, solution 10 mg/mL Epidural Sagent Pharmaceuticals 2014-09-23 Not applicable US Ropivacaine Hydrochloride Injection, solution 5 mg/mL Epidural; Infiltration; Perineural Akorn 2016-04-11 Not applicable US Ropivacaine Hydrochloride Injection, solution 5 mg/mL Epidural; Infiltration; Perineural Auro Medics Pharma Llc 2016-09-15 Not applicable US Ropivacaine Hydrochloride Injection, solution 10 mg/mL Parenteral Sandoz 2014-07-24 Not applicable US Ropivacaine Hydrochloride Injection, solution 7.5 mg/mL Epidural; Perineural Hospira, Inc. 2014-09-23 Not applicable US Ropivacaine Hydrochloride Injection, solution 7.5 mg/mL Epidural; Perineural Sagent Pharmaceuticals 2014-09-23 Not applicable US Ropivacaine Hydrochloride Injection, solution 10 mg/mL Epidural Auro Medics Pharma Llc 2016-09-15 Not applicable US Ropivacaine Hydrochloride Injection, solution 2 mg/mL Epidural; Infiltration; Perineural Hospira, Inc. 2014-09-23 Not applicable US Ropivacaine Hydrochloride Injection, solution 10 mg/mL Epidural Hospira, Inc. 2014-09-23 Not applicable US Ropivacaine Hydrochloride Injection, solution 5 mg/mL Epidural; Infiltration; Perineural Auro Medics Pharma Llc 2016-09-15 Not applicable US Ropivacaine Hydrochloride Injection, solution 5 mg/mL Epidural; Infiltration; Perineural Sagent Pharmaceuticals 2014-09-23 Not applicable US Ropivacaine Hydrochloride Injection, solution 2 mg/mL Epidural; Infiltration; Perineural Sagent Pharmaceuticals 2014-09-23 Not applicable US Ropivacaine Hydrochloride Injection, solution 10 mg/mL Epidural Auro Medics Pharma Llc 2016-09-15 Not applicable US - Approved Over the Counter Products
- Not Available
- Unapproved/Other Products
- Not Available
- International/Other Brands
- Not Available
- Brand mixtures
- Not Available
- Categories
- Amides
- Anesthetics
- Anesthetics, Local
- Central Nervous System Agents
- Central Nervous System Depressants
- Cytochrome P-450 CYP1A2 Substrates
- Cytochrome P-450 CYP2B6 Substrates
- Cytochrome P-450 CYP2D6 Substrates
- Cytochrome P-450 CYP3A4 Substrates
- Hypotensive Agents
- Nervous System
- Peripheral Nervous System Agents
- Sensory System Agents
- UNII
- 7IO5LYA57N
- CAS number
- 84057-95-4
- Weight
- Average: 274.4011
Monoisotopic: 274.204513464 - Chemical Formula
- C17H26N2O
- InChI Key
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N
- InChI
- InChI=1S/C17H26N2O/c1-4-11-19-12-6-5-10-15(19)17(20)18-16-13(2)8-7-9-14(16)3/h7-9,15H,4-6,10-12H2,1-3H3,(H,18,20)/t15-/m0/s1
- IUPAC Name
- (2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide
- SMILES
- CCCN1CCCC[[email protected]]1C(=O)NC1=C(C)C=CC=C1C
Pharmacology
- Indication
Used in obstetric anesthesia and regional anesthesia for surgery.
- Structured Indications
- Pharmacodynamics
Ropivacaine, a local anesthetic agent, is indicated for the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures.
- Mechanism of action
Local anesthetics such as Ropivacaine block the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. Specifically, they block the sodium-channel and decrease chances of depolarization and consequent action potentials. In general, the progression of anesthesia is related to the diameter, myelination and conduction velocity of affected nerve fibers.
Target Actions Organism ASodium channel protein type 10 subunit alpha inhibitorHuman - Absorption
Bioavailability is 87%–98% following epidural administration.
- Volume of distribution
- Not Available
- Protein binding
94%, mainly to a1-acid glycoprotein
- Metabolism
Hepatic
Reactions:
- Route of elimination
Ropivacaine is extensively metabolized in the liver, predominantly by aromatic hydroxylation mediated by cytochrome P4501A to 3-hydroxy ropivacaine. After a single IV dose approximately 37% of the total dose is excreted in the urine as both free and conjugated 3-hydroxy ropivacaine. In total, 86% of the ropivacaine dose is excreted in the urine after intravenous administration of which only 1% relates to unchanged drug.
- Half life
Approximately 4.2 hours.
- Clearance
- 387 +/- 107 mL/min
- unbound plasma clearance=7.2 +/- 1.6 L/min
- Toxicity
Systemic exposure to excessive quantities of ropivacaine mainly result in central nervous system (CNS) and cardiovascular effects – CNS effects usually occur at lower blood plasma concentrations and additional cardiovascular effects present at higher concentrations, though cardiovascular collapse may also occur with low concentrations. CNS effects may include CNS excitation (nervousness, tingling around the mouth, tinnitus, tremor, dizziness, blurred vision, seizures) followed by depression (drowsiness, loss of consciousness, respiratory depression and apnea). Cardiovascular effects include hypotension, bradycardia, arrhythmias, and/or cardiac arrest – some of which may be due to hypoxemia secondary to respiratory depression.
- Affected organisms
- Humans and other mammals
- Pathways
Pathway Category Ropivacaine Action Pathway Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 7-Nitroindazole The risk or severity of adverse effects can be increased when Ropivacaine is combined with 7-Nitroindazole. Experimental Abiraterone The serum concentration of Ropivacaine can be increased when it is combined with Abiraterone. Approved Acebutolol The risk or severity of adverse effects can be increased when Acebutolol is combined with Ropivacaine. Approved Acepromazine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Acepromazine. Approved, Vet Approved Aceprometazine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Aceprometazine. Approved Acetazolamide The risk or severity of adverse effects can be increased when Ropivacaine is combined with Acetazolamide. Approved, Vet Approved Adipiplon The risk or severity of adverse effects can be increased when Ropivacaine is combined with adipiplon. Investigational Agomelatine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Agomelatine. Approved, Investigational Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Ropivacaine. Approved Alfaxalone The risk or severity of adverse effects can be increased when Ropivacaine is combined with Alfaxalone. Vet Approved Alfentanil The risk or severity of adverse effects can be increased when Ropivacaine is combined with Alfentanil. Approved, Illicit Aliskiren The risk or severity of adverse effects can be increased when Aliskiren is combined with Ropivacaine. Approved, Investigational Allopregnanolone The risk or severity of adverse effects can be increased when Ropivacaine is combined with Sage 547. Investigational Alphacetylmethadol The risk or severity of adverse effects can be increased when Ropivacaine is combined with Alphacetylmethadol. Experimental, Illicit Alprazolam The risk or severity of adverse effects can be increased when Ropivacaine is combined with Alprazolam. Approved, Illicit, Investigational Amifostine The risk or severity of adverse effects can be increased when Amifostine is combined with Ropivacaine. Approved, Investigational Amiloride The risk or severity of adverse effects can be increased when Amiloride is combined with Ropivacaine. Approved Amiodarone The metabolism of Ropivacaine can be decreased when combined with Amiodarone. Approved, Investigational Amisulpride The risk or severity of adverse effects can be increased when Ropivacaine is combined with Amisulpride. Approved, Investigational Amitriptyline The risk or severity of adverse effects can be increased when Ropivacaine is combined with Amitriptyline. Approved Amlodipine The risk or severity of adverse effects can be increased when Amlodipine is combined with Ropivacaine. Approved Amobarbital The risk or severity of adverse effects can be increased when Ropivacaine is combined with Amobarbital. Approved, Illicit Amoxapine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Amoxapine. Approved Amperozide The risk or severity of adverse effects can be increased when Ropivacaine is combined with Amperozide. Experimental Amphotericin B The risk or severity of adverse effects can be increased when Amphotericin B is combined with Ropivacaine. Approved, Investigational Amyl Nitrite The risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Ropivacaine. Approved Apomorphine The risk or severity of adverse effects can be increased when Apomorphine is combined with Ropivacaine. Approved, Investigational Apraclonidine The risk or severity of adverse effects can be increased when Apraclonidine is combined with Ropivacaine. Approved Aprepitant The serum concentration of Ropivacaine can be increased when it is combined with Aprepitant. Approved, Investigational Aripiprazole Aripiprazole may increase the hypotensive activities of Ropivacaine. Approved, Investigational Arotinolol The risk or severity of adverse effects can be increased when Arotinolol is combined with Ropivacaine. Approved Arsenic trioxide The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ropivacaine. Approved, Investigational Artemether The metabolism of Ropivacaine can be decreased when combined with Artemether. Approved Articaine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Articaine. Approved Asenapine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Asenapine. Approved Atazanavir The metabolism of Ropivacaine can be decreased when combined with Atazanavir. Approved, Investigational Atenolol The risk or severity of adverse effects can be increased when Atenolol is combined with Ropivacaine. Approved Atomoxetine The metabolism of Ropivacaine can be decreased when combined with Atomoxetine. Approved Azaperone The risk or severity of adverse effects can be increased when Ropivacaine is combined with Azaperone. Vet Approved Azelastine Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Approved Azelastine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Azelastine. Approved Azilsartan medoxomil The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Ropivacaine. Approved Azithromycin The metabolism of Ropivacaine can be decreased when combined with Azithromycin. Approved Baclofen The risk or severity of adverse effects can be increased when Ropivacaine is combined with Baclofen. Approved Barbexaclone Barbexaclone may increase the hypotensive activities of Ropivacaine. Experimental Barbital The risk or severity of adverse effects can be increased when Ropivacaine is combined with Barbital. Illicit Barnidipine The risk or severity of adverse effects can be increased when Barnidipine is combined with Ropivacaine. Approved Benazepril The risk or severity of adverse effects can be increased when Benazepril is combined with Ropivacaine. Approved, Investigational Bendroflumethiazide The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Ropivacaine. Approved Benperidol The risk or severity of adverse effects can be increased when Ropivacaine is combined with Benperidol. Investigational Benzocaine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Benzocaine. Approved Benzyl alcohol The risk or severity of adverse effects can be increased when Ropivacaine is combined with Benzyl alcohol. Approved Bepridil The risk or severity of adverse effects can be increased when Bepridil is combined with Ropivacaine. Approved, Withdrawn Betaxolol The metabolism of Ropivacaine can be decreased when combined with Betaxolol. Approved Bexarotene The serum concentration of Ropivacaine can be decreased when it is combined with Bexarotene. Approved, Investigational Bisoprolol The risk or severity of adverse effects can be increased when Bisoprolol is combined with Ropivacaine. Approved Boceprevir The metabolism of Ropivacaine can be decreased when combined with Boceprevir. Withdrawn Bortezomib The metabolism of Ropivacaine can be decreased when combined with Bortezomib. Approved, Investigational Bosentan The serum concentration of Ropivacaine can be decreased when it is combined with Bosentan. Approved, Investigational Bretylium The risk or severity of adverse effects can be increased when Bretylium is combined with Ropivacaine. Approved Brexpiprazole The risk or severity of adverse effects can be increased when Ropivacaine is combined with Brexpiprazole. Approved Brimonidine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Brimonidine. Approved Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine. Approved Bromazepam The risk or severity of adverse effects can be increased when Ropivacaine is combined with Bromazepam. Approved, Illicit Bromocriptine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Ropivacaine. Approved, Investigational Brompheniramine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Brompheniramine. Approved Brotizolam The risk or severity of adverse effects can be increased when Ropivacaine is combined with Brotizolam. Approved, Withdrawn Bumetanide The risk or severity of adverse effects can be increased when Bumetanide is combined with Ropivacaine. Approved Bupivacaine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Bupivacaine. Approved, Investigational Buprenorphine Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Approved, Illicit, Investigational, Vet Approved Bupropion The metabolism of Ropivacaine can be decreased when combined with Bupropion. Approved Buspirone The risk or severity of adverse effects can be increased when Ropivacaine is combined with Buspirone. Approved, Investigational Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Ropivacaine. Approved, Illicit Butacaine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Butacaine. Vet Approved Butalbital The risk or severity of adverse effects can be increased when Ropivacaine is combined with Butalbital. Approved, Illicit Butamben The risk or severity of adverse effects can be increased when Ropivacaine is combined with Butamben. Approved Butethal The risk or severity of adverse effects can be increased when Ropivacaine is combined with Butethal. Approved, Illicit Butorphanol The risk or severity of adverse effects can be increased when Ropivacaine is combined with Butorphanol. Approved, Illicit, Vet Approved Caffeine The metabolism of Ropivacaine can be decreased when combined with Caffeine. Approved Canagliflozin The risk or severity of adverse effects can be increased when Canagliflozin is combined with Ropivacaine. Approved Candesartan The risk or severity of adverse effects can be increased when Candesartan is combined with Ropivacaine. Approved Captopril The risk or severity of adverse effects can be increased when Captopril is combined with Ropivacaine. Approved Carbamazepine The metabolism of Ropivacaine can be increased when combined with Carbamazepine. Approved, Investigational Carbetocin The risk or severity of adverse effects can be increased when Carbetocin is combined with Ropivacaine. Approved Carbinoxamine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Carbinoxamine. Approved Carfentanil The risk or severity of adverse effects can be increased when Ropivacaine is combined with Carfentanil. Illicit, Vet Approved Carisoprodol The risk or severity of adverse effects can be increased when Ropivacaine is combined with Carisoprodol. Approved Carteolol The risk or severity of adverse effects can be increased when Carteolol is combined with Ropivacaine. Approved Carvedilol The risk or severity of adverse effects can be increased when Carvedilol is combined with Ropivacaine. Approved, Investigational Celecoxib The metabolism of Ropivacaine can be decreased when combined with Celecoxib. Approved, Investigational Ceritinib The serum concentration of Ropivacaine can be increased when it is combined with Ceritinib. Approved Cetirizine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Cetirizine. Approved Chloral hydrate The risk or severity of adverse effects can be increased when Ropivacaine is combined with Chloral hydrate. Approved, Illicit, Vet Approved Chlordiazepoxide The risk or severity of adverse effects can be increased when Ropivacaine is combined with Chlordiazepoxide. Approved, Illicit Chlormezanone The risk or severity of adverse effects can be increased when Ropivacaine is combined with Chlormezanone. Approved, Withdrawn Chloroprocaine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Chloroprocaine. Approved Chloroquine The metabolism of Ropivacaine can be decreased when combined with Chloroquine. Approved, Vet Approved Chlorothiazide The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Ropivacaine. Approved, Vet Approved Chlorphenamine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Chlorphenamine. Approved Chlorpromazine The metabolism of Ropivacaine can be decreased when combined with Chlorpromazine. Approved, Vet Approved Chlorprothixene The risk or severity of adverse effects can be increased when Ropivacaine is combined with Chlorprothixene. Approved, Withdrawn Chlorthalidone The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Ropivacaine. Approved Chlorzoxazone The risk or severity of adverse effects can be increased when Ropivacaine is combined with Chlorzoxazone. Approved Cholecalciferol The metabolism of Ropivacaine can be decreased when combined with Cholecalciferol. Approved, Nutraceutical Cilazapril The risk or severity of adverse effects can be increased when Cilazapril is combined with Ropivacaine. Approved Cilnidipine The risk or severity of adverse effects can be increased when Cilnidipine is combined with Ropivacaine. Approved Cimetidine The metabolism of Ropivacaine can be decreased when combined with Cimetidine. Approved Cinacalcet The metabolism of Ropivacaine can be decreased when combined with Cinacalcet. Approved Cinchocaine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Cinchocaine. Approved, Vet Approved Ciprofloxacin The serum concentration of Ropivacaine can be increased when it is combined with Ciprofloxacin. Approved, Investigational Citalopram The metabolism of Ropivacaine can be decreased when combined with Citalopram. Approved Clarithromycin The metabolism of Ropivacaine can be decreased when combined with Clarithromycin. Approved Clemastine The metabolism of Ropivacaine can be decreased when combined with Clemastine. Approved Clevidipine The risk or severity of adverse effects can be increased when Clevidipine is combined with Ropivacaine. Approved Clidinium The risk or severity of adverse effects can be increased when Ropivacaine is combined with Clidinium. Approved Clobazam The metabolism of Ropivacaine can be decreased when combined with Clobazam. Approved, Illicit Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Ropivacaine. Approved, Investigational clomethiazole The risk or severity of adverse effects can be increased when Ropivacaine is combined with clomethiazole. Investigational Clomipramine The metabolism of Ropivacaine can be decreased when combined with Clomipramine. Approved, Vet Approved Clonazepam The risk or severity of adverse effects can be increased when Ropivacaine is combined with Clonazepam. Approved, Illicit Clonidine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Clonidine. Approved Clopidogrel The metabolism of Ropivacaine can be decreased when combined with Clopidogrel. Approved, Nutraceutical Clorazepate The risk or severity of adverse effects can be increased when Ropivacaine is combined with Clorazepate. Approved, Illicit Clotrimazole The metabolism of Ropivacaine can be decreased when combined with Clotrimazole. Approved, Vet Approved Clozapine The metabolism of Ropivacaine can be decreased when combined with Clozapine. Approved Cobicistat The serum concentration of Ropivacaine can be increased when it is combined with Cobicistat. Approved Cocaine The metabolism of Ropivacaine can be decreased when combined with Cocaine. Approved, Illicit Codeine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Codeine. Approved, Illicit Conivaptan The serum concentration of Ropivacaine can be increased when it is combined with Conivaptan. Approved, Investigational Crizotinib The metabolism of Ropivacaine can be decreased when combined with Crizotinib. Approved Cyclizine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Cyclizine. Approved Cyclobenzaprine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Cyclobenzaprine. Approved Cyclosporine The metabolism of Ropivacaine can be decreased when combined with Cyclosporine. Approved, Investigational, Vet Approved Cyproheptadine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Cyproheptadine. Approved Cyproterone acetate The serum concentration of Ropivacaine can be decreased when it is combined with Cyproterone acetate. Approved, Investigational Dabrafenib The serum concentration of Ropivacaine can be decreased when it is combined with Dabrafenib. Approved Dantrolene The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dantrolene. Approved Dapagliflozin The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Ropivacaine. Approved Dapiprazole The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dapiprazole. Approved Dapoxetine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dapoxetine. Investigational Darifenacin The metabolism of Ropivacaine can be decreased when combined with Darifenacin. Approved, Investigational Darunavir The serum concentration of Ropivacaine can be increased when it is combined with Darunavir. Approved Dasatinib The serum concentration of Ropivacaine can be increased when it is combined with Dasatinib. Approved, Investigational Deferasirox The serum concentration of Ropivacaine can be decreased when it is combined with Deferasirox. Approved, Investigational Delavirdine The metabolism of Ropivacaine can be decreased when combined with Delavirdine. Approved Deramciclane The risk or severity of adverse effects can be increased when Ropivacaine is combined with deramciclane. Investigational Desflurane The risk or severity of adverse effects can be increased when Ropivacaine is combined with Desflurane. Approved Desipramine The metabolism of Ropivacaine can be decreased when combined with Desipramine. Approved Desloratadine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Desloratadine. Approved, Investigational Desvenlafaxine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Desvenlafaxine. Approved Detomidine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Detomidine. Vet Approved Dexamethasone The serum concentration of Ropivacaine can be decreased when it is combined with Dexamethasone. Approved, Investigational, Vet Approved Dexbrompheniramine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dexbrompheniramine. Approved Dexmedetomidine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dexmedetomidine. Approved, Vet Approved Dextromoramide The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dextromoramide. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dextropropoxyphene. Approved, Illicit, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dezocine. Approved Diazepam The risk or severity of adverse effects can be increased when Ropivacaine is combined with Diazepam. Approved, Illicit, Vet Approved Diclofenamide The risk or severity of adverse effects can be increased when Diclofenamide is combined with Ropivacaine. Approved Difenoxin The risk or severity of adverse effects can be increased when Ropivacaine is combined with Difenoxin. Approved, Illicit Dihydrocodeine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dihydrocodeine. Approved, Illicit Dihydroergotamine The metabolism of Ropivacaine can be decreased when combined with Dihydroergotamine. Approved Dihydroetorphine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dihydroetorphine. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dihydromorphine. Experimental, Illicit Diltiazem The metabolism of Ropivacaine can be decreased when combined with Diltiazem. Approved Dimenhydrinate The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dimenhydrinate. Approved Dinutuximab The risk or severity of adverse effects can be increased when Dinutuximab is combined with Ropivacaine. Approved Diphenhydramine The metabolism of Ropivacaine can be decreased when combined with Diphenhydramine. Approved Diphenoxylate The risk or severity of adverse effects can be increased when Ropivacaine is combined with Diphenoxylate. Approved, Illicit Dipyridamole The risk or severity of adverse effects can be increased when Dipyridamole is combined with Ropivacaine. Approved Doramectin The risk or severity of adverse effects can be increased when Ropivacaine is combined with Doramectin. Vet Approved Doxazosin The risk or severity of adverse effects can be increased when Doxazosin is combined with Ropivacaine. Approved Doxepin The risk or severity of adverse effects can be increased when Ropivacaine is combined with Doxepin. Approved Doxorubicin The metabolism of Ropivacaine can be decreased when combined with Doxorubicin. Approved, Investigational Doxycycline The metabolism of Ropivacaine can be decreased when combined with Doxycycline. Approved, Investigational, Vet Approved Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine. Approved, Vet Approved DPDPE The risk or severity of adverse effects can be increased when Ropivacaine is combined with DPDPE. Investigational Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine. Approved, Illicit Dronedarone The metabolism of Ropivacaine can be decreased when combined with Dronedarone. Approved Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine. Approved, Vet Approved Drotebanol The risk or severity of adverse effects can be increased when Ropivacaine is combined with Drotebanol. Experimental, Illicit Duloxetine Ropivacaine may increase the orthostatic hypotensive activities of Duloxetine. Approved Dyclonine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dyclonine. Approved Ecgonine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ecgonine. Experimental, Illicit Ecopipam The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ecopipam. Investigational Efavirenz The serum concentration of Ropivacaine can be decreased when it is combined with Efavirenz. Approved, Investigational Efonidipine The risk or severity of adverse effects can be increased when Efonidipine is combined with Ropivacaine. Approved Eliglustat The metabolism of Ropivacaine can be decreased when combined with Eliglustat. Approved Eltanolone The risk or severity of adverse effects can be increased when Ropivacaine is combined with Pregnanolone. Investigational Empagliflozin The risk or severity of adverse effects can be increased when Empagliflozin is combined with Ropivacaine. Approved Enalapril The risk or severity of adverse effects can be increased when Enalapril is combined with Ropivacaine. Approved, Vet Approved Enalaprilat The risk or severity of adverse effects can be increased when Enalaprilat is combined with Ropivacaine. Approved Enflurane The risk or severity of adverse effects can be increased when Enflurane is combined with Ropivacaine. Approved, Vet Approved Entacapone The risk or severity of adverse effects can be increased when Ropivacaine is combined with Entacapone. Approved, Investigational Enzalutamide The serum concentration of Ropivacaine can be decreased when it is combined with Enzalutamide. Approved Eplerenone The risk or severity of adverse effects can be increased when Eplerenone is combined with Ropivacaine. Approved Epoprostenol The risk or severity of adverse effects can be increased when Epoprostenol is combined with Ropivacaine. Approved Eprosartan The risk or severity of adverse effects can be increased when Eprosartan is combined with Ropivacaine. Approved Erythromycin The metabolism of Ropivacaine can be decreased when combined with Erythromycin. Approved, Vet Approved Escitalopram The risk or severity of adverse effects can be increased when Ropivacaine is combined with Escitalopram. Approved, Investigational Eslicarbazepine acetate The serum concentration of Ropivacaine can be decreased when it is combined with Eslicarbazepine acetate. Approved Esmolol The risk or severity of adverse effects can be increased when Esmolol is combined with Ropivacaine. Approved Estazolam The risk or severity of adverse effects can be increased when Ropivacaine is combined with Estazolam. Approved, Illicit Eszopiclone The risk or severity of adverse effects can be increased when Ropivacaine is combined with Eszopiclone. Approved Etacrynic acid The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Ropivacaine. Approved Ethanol Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Approved Ethchlorvynol The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ropivacaine. Approved, Illicit, Withdrawn Ethosuximide The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ethosuximide. Approved Ethotoin The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ethotoin. Approved Ethyl carbamate The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ethyl carbamate. Withdrawn Ethyl loflazepate The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ethyl loflazepate. Approved, Illicit Ethylmorphine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ethylmorphine. Approved, Illicit Etidocaine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Etidocaine. Approved Etifoxine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Etifoxine. Withdrawn Etizolam The risk or severity of adverse effects can be increased when Ropivacaine is combined with Etizolam. Approved Etomidate The risk or severity of adverse effects can be increased when Etomidate is combined with Ropivacaine. Approved Etoperidone The risk or severity of adverse effects can be increased when Ropivacaine is combined with Etoperidone. Approved Etorphine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Etorphine. Illicit, Vet Approved Etravirine The serum concentration of Ropivacaine can be decreased when it is combined with Etravirine. Approved Ezogabine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ezogabine. Approved Felbamate The risk or severity of adverse effects can be increased when Ropivacaine is combined with Felbamate. Approved Felodipine The risk or severity of adverse effects can be increased when Felodipine is combined with Ropivacaine. Approved, Investigational Fencamfamine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Fencamfamine. Approved, Illicit, Withdrawn Fenoldopam The risk or severity of adverse effects can be increased when Fenoldopam is combined with Ropivacaine. Approved Fentanyl The risk or severity of adverse effects can be increased when Ropivacaine is combined with Fentanyl. Approved, Illicit, Investigational, Vet Approved Fexofenadine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Fexofenadine. Approved Fimasartan The risk or severity of adverse effects can be increased when Fimasartan is combined with Ropivacaine. Approved Flibanserin The risk or severity of adverse effects can be increased when Ropivacaine is combined with Flibanserin. Approved Fluconazole The metabolism of Ropivacaine can be decreased when combined with Fluconazole. Approved Fludiazepam The risk or severity of adverse effects can be increased when Ropivacaine is combined with Fludiazepam. Approved, Illicit Flunarizine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Flunarizine. Approved Flunitrazepam The risk or severity of adverse effects can be increased when Ropivacaine is combined with Flunitrazepam. Approved, Illicit Fluoxetine The metabolism of Ropivacaine can be decreased when combined with Fluoxetine. Approved, Vet Approved Flupentixol The risk or severity of adverse effects can be increased when Ropivacaine is combined with Flupentixol. Approved, Withdrawn Fluphenazine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Fluphenazine. Approved Flurazepam The risk or severity of adverse effects can be increased when Ropivacaine is combined with Flurazepam. Approved, Illicit Fluspirilene The risk or severity of adverse effects can be increased when Ropivacaine is combined with Fluspirilene. Approved Fluticasone propionate The risk or severity of adverse effects can be increased when Ropivacaine is combined with Fluticasone Propionate. Approved Fluvoxamine The serum concentration of Ropivacaine can be increased when it is combined with Fluvoxamine. Approved, Investigational Fosamprenavir The metabolism of Ropivacaine can be decreased when combined with Fosamprenavir. Approved Fosaprepitant The serum concentration of Ropivacaine can be increased when it is combined with Fosaprepitant. Approved Fosinopril The risk or severity of adverse effects can be increased when Fosinopril is combined with Ropivacaine. Approved Fosphenytoin The metabolism of Ropivacaine can be increased when combined with Fosphenytoin. Approved Fospropofol The risk or severity of adverse effects can be increased when Ropivacaine is combined with Fospropofol. Approved, Illicit Furosemide The risk or severity of adverse effects can be increased when Furosemide is combined with Ropivacaine. Approved, Vet Approved Fusidic Acid The serum concentration of Ropivacaine can be increased when it is combined with Fusidic Acid. Approved Gabapentin The risk or severity of adverse effects can be increased when Ropivacaine is combined with Gabapentin. Approved, Investigational Gabapentin Enacarbil The risk or severity of adverse effects can be increased when Ropivacaine is combined with gabapentin enacarbil. Approved Gamma Hydroxybutyric Acid The risk or severity of adverse effects can be increased when Ropivacaine is combined with Gamma Hydroxybutyric Acid. Approved, Illicit Gepirone The risk or severity of adverse effects can be increased when Ropivacaine is combined with Gepirone. Investigational Glutethimide The risk or severity of adverse effects can be increased when Ropivacaine is combined with Glutethimide. Approved, Illicit Guanfacine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Guanfacine. Approved, Investigational Halazepam The risk or severity of adverse effects can be increased when Ropivacaine is combined with Halazepam. Approved, Illicit, Withdrawn Haloperidol The metabolism of Ropivacaine can be decreased when combined with Haloperidol. Approved Halothane The risk or severity of adverse effects can be increased when Ropivacaine is combined with Halothane. Approved, Vet Approved Heroin The risk or severity of adverse effects can be increased when Ropivacaine is combined with Heroin. Approved, Illicit Hexobarbital The risk or severity of adverse effects can be increased when Ropivacaine is combined with Hexobarbital. Approved Hyaluronidase The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Ropivacaine. Approved, Investigational Hydralazine The risk or severity of adverse effects can be increased when Hydralazine is combined with Ropivacaine. Approved Hydrochlorothiazide The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Ropivacaine. Approved, Vet Approved Hydrocodone Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. Approved, Illicit Hydroflumethiazide The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Ropivacaine. Approved Hydromorphone The risk or severity of adverse effects can be increased when Ropivacaine is combined with Hydromorphone. Approved, Illicit Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine. Approved Idelalisib The serum concentration of Ropivacaine can be increased when it is combined with Idelalisib. Approved Iloperidone The risk or severity of adverse effects can be increased when Ropivacaine is combined with Iloperidone. Approved Iloprost The risk or severity of adverse effects can be increased when Iloprost is combined with Ropivacaine. Approved, Investigational Imatinib The metabolism of Ropivacaine can be decreased when combined with Imatinib. Approved Imidapril The risk or severity of adverse effects can be increased when Imidapril is combined with Ropivacaine. Investigational Imipramine The metabolism of Ropivacaine can be decreased when combined with Imipramine. Approved Indalpine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Indalpine. Investigational, Withdrawn Indapamide The risk or severity of adverse effects can be increased when Indapamide is combined with Ropivacaine. Approved Indinavir The metabolism of Ropivacaine can be decreased when combined with Indinavir. Approved Indoramin The risk or severity of adverse effects can be increased when Indoramin is combined with Ropivacaine. Withdrawn Irbesartan The risk or severity of adverse effects can be increased when Irbesartan is combined with Ropivacaine. Approved, Investigational Isavuconazonium The metabolism of Ropivacaine can be decreased when combined with Isavuconazonium. Approved, Investigational Isocarboxazid The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Ropivacaine. Approved Isoflurane The risk or severity of adverse effects can be increased when Ropivacaine is combined with Isoflurane. Approved, Vet Approved Isoniazid The metabolism of Ropivacaine can be decreased when combined with Isoniazid. Approved Isosorbide Dinitrate The risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Ropivacaine. Approved Isosorbide Mononitrate The risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Ropivacaine. Approved Isoxsuprine The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Ropivacaine. Approved, Withdrawn Isradipine The metabolism of Ropivacaine can be decreased when combined with Isradipine. Approved Itraconazole The metabolism of Ropivacaine can be decreased when combined with Itraconazole. Approved, Investigational Ivacaftor The serum concentration of Ropivacaine can be increased when it is combined with Ivacaftor. Approved Ketamine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ketamine. Approved, Vet Approved Ketazolam The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ketazolam. Approved Ketobemidone The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ketobemidone. Approved Ketoconazole The metabolism of Ropivacaine can be decreased when combined with Ketoconazole. Approved, Investigational Labetalol The risk or severity of adverse effects can be increased when Labetalol is combined with Ropivacaine. Approved Lacidipine The risk or severity of adverse effects can be increased when Lacidipine is combined with Ropivacaine. Approved Lamotrigine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Lamotrigine. Approved, Investigational Lercanidipine The risk or severity of adverse effects can be increased when Lercanidipine is combined with Ropivacaine. Approved, Investigational Levetiracetam The risk or severity of adverse effects can be increased when Ropivacaine is combined with Levetiracetam. Approved, Investigational Levobunolol The risk or severity of adverse effects can be increased when Levobunolol is combined with Ropivacaine. Approved Levobupivacaine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Levobupivacaine. Approved Levocabastine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Levocabastine. Approved Levocetirizine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Levocetirizine. Approved Levodopa Ropivacaine may increase the orthostatic hypotensive activities of Levodopa. Approved Levomethadyl Acetate The risk or severity of adverse effects can be increased when Ropivacaine is combined with Levomethadyl Acetate. Approved Levomilnacipran The risk or severity of adverse effects can be increased when Ropivacaine is combined with Levomilnacipran. Approved Levorphanol The risk or severity of adverse effects can be increased when Ropivacaine is combined with Levorphanol. Approved Levosimendan The risk or severity of adverse effects can be increased when Levosimendan is combined with Ropivacaine. Approved, Investigational Lidocaine The metabolism of Ropivacaine can be decreased when combined with Lidocaine. Approved, Vet Approved Lisinopril The risk or severity of adverse effects can be increased when Lisinopril is combined with Ropivacaine. Approved, Investigational Lithium The risk or severity of adverse effects can be increased when Ropivacaine is combined with Lithium. Approved Lofentanil The risk or severity of adverse effects can be increased when Ropivacaine is combined with Lofentanil. Illicit Lofexidine The risk or severity of adverse effects can be increased when Lofexidine is combined with Ropivacaine. Approved, Investigational Lopinavir The metabolism of Ropivacaine can be decreased when combined with Lopinavir. Approved Loratadine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Loratadine. Approved Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Ropivacaine. Approved Lorcaserin The metabolism of Ropivacaine can be decreased when combined with Lorcaserin. Approved Losartan The risk or severity of adverse effects can be increased when Losartan is combined with Ropivacaine. Approved Lovastatin The metabolism of Ropivacaine can be decreased when combined with Lovastatin. Approved, Investigational Loxapine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Loxapine. Approved Luliconazole The serum concentration of Ropivacaine can be increased when it is combined with Luliconazole. Approved Lumacaftor The serum concentration of Ropivacaine can be decreased when it is combined with Lumacaftor. Approved Lumefantrine The metabolism of Ropivacaine can be decreased when combined with Lumefantrine. Approved Lurasidone The risk or severity of adverse effects can be increased when Ropivacaine is combined with Lurasidone. Approved Magnesium Sulfate Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine. Approved, Vet Approved Mannitol The risk or severity of adverse effects can be increased when Mannitol is combined with Ropivacaine. Approved, Investigational Maprotiline The risk or severity of adverse effects can be increased when Ropivacaine is combined with Maprotiline. Approved Mecamylamine The risk or severity of adverse effects can be increased when Mecamylamine is combined with Ropivacaine. Approved Meclizine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Meclizine. Approved Medetomidine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Medetomidine. Vet Approved Melatonin The risk or severity of adverse effects can be increased when Ropivacaine is combined with Melatonin. Approved, Nutraceutical, Vet Approved Melperone The risk or severity of adverse effects can be increased when Ropivacaine is combined with Melperone. Approved Mepivacaine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Mepivacaine. Approved, Vet Approved Meprobamate The risk or severity of adverse effects can be increased when Ropivacaine is combined with Meprobamate. Approved, Illicit Mesoridazine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Mesoridazine. Approved Metaxalone The risk or severity of adverse effects can be increased when Ropivacaine is combined with Metaxalone. Approved Methadone The metabolism of Ropivacaine can be decreased when combined with Methadone. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Ropivacaine is combined with Methadyl Acetate. Approved, Illicit Methapyrilene The risk or severity of adverse effects can be increased when Ropivacaine is combined with Methapyrilene. Withdrawn Methaqualone The risk or severity of adverse effects can be increased when Ropivacaine is combined with Methaqualone. Illicit, Withdrawn Methazolamide The risk or severity of adverse effects can be increased when Methazolamide is combined with Ropivacaine. Approved Methocarbamol The risk or severity of adverse effects can be increased when Ropivacaine is combined with Methocarbamol. Approved, Vet Approved Methohexital The risk or severity of adverse effects can be increased when Ropivacaine is combined with Methohexital. Approved Methotrimeprazine Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. Approved Methoxyflurane The risk or severity of adverse effects can be increased when Ropivacaine is combined with Methoxyflurane. Approved, Vet Approved Methsuximide The risk or severity of adverse effects can be increased when Ropivacaine is combined with Methsuximide. Approved Methyclothiazide The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Ropivacaine. Approved Methyldopa The risk or severity of adverse effects can be increased when Methyldopa is combined with Ropivacaine. Approved Methylecgonine The risk or severity of adverse effects can be increased when Ropivacaine is combined with ECGONINE METHYL ESTER. Experimental Methylphenobarbital The risk or severity of adverse effects can be increased when Ropivacaine is combined with Methylphenobarbital. Approved Metipranolol The risk or severity of adverse effects can be increased when Metipranolol is combined with Ropivacaine. Approved Metolazone The risk or severity of adverse effects can be increased when Metolazone is combined with Ropivacaine. Approved Metoprolol The metabolism of Ropivacaine can be decreased when combined with Metoprolol. Approved, Investigational Metyrosine Ropivacaine may increase the sedative activities of Metyrosine. Approved Mexiletine The metabolism of Ropivacaine can be decreased when combined with Mexiletine. Approved Midazolam The risk or severity of adverse effects can be increased when Ropivacaine is combined with Midazolam. Approved, Illicit Mifepristone The serum concentration of Ropivacaine can be increased when it is combined with Mifepristone. Approved, Investigational Milnacipran The risk or severity of adverse effects can be increased when Ropivacaine is combined with Milnacipran. Approved Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine. Approved, Investigational Minoxidil The risk or severity of adverse effects can be increased when Minoxidil is combined with Ropivacaine. Approved Mirabegron The metabolism of Ropivacaine can be decreased when combined with Mirabegron. Approved Mirtazapine Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. Approved Mitotane The serum concentration of Ropivacaine can be decreased when it is combined with Mitotane. Approved Modafinil The serum concentration of Ropivacaine can be decreased when it is combined with Modafinil. Approved, Investigational Moexipril The risk or severity of adverse effects can be increased when Moexipril is combined with Ropivacaine. Approved Molindone The risk or severity of adverse effects can be increased when Ropivacaine is combined with Molindone. Approved Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Ropivacaine. Approved, Investigational Moxonidine The risk or severity of adverse effects can be increased when Moxonidine is combined with Ropivacaine. Approved Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine. Approved, Investigational Nadolol The risk or severity of adverse effects can be increased when Nadolol is combined with Ropivacaine. Approved Nafcillin The serum concentration of Ropivacaine can be decreased when it is combined with Nafcillin. Approved Nalbuphine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Nalbuphine. Approved Nebivolol The risk or severity of adverse effects can be increased when Nebivolol is combined with Ropivacaine. Approved, Investigational Nefazodone The metabolism of Ropivacaine can be decreased when combined with Nefazodone. Approved, Withdrawn Nelfinavir The metabolism of Ropivacaine can be decreased when combined with Nelfinavir. Approved Nesiritide The risk or severity of adverse effects can be increased when Nesiritide is combined with Ropivacaine. Approved, Investigational Netupitant The serum concentration of Ropivacaine can be increased when it is combined with Netupitant. Approved Nevirapine The metabolism of Ropivacaine can be increased when combined with Nevirapine. Approved Nicardipine The metabolism of Ropivacaine can be decreased when combined with Nicardipine. Approved Nicorandil Nicorandil may increase the hypotensive activities of Ropivacaine. Approved Nifedipine The risk or severity of adverse effects can be increased when Nifedipine is combined with Ropivacaine. Approved Nilotinib The metabolism of Ropivacaine can be decreased when combined with Nilotinib. Approved, Investigational Nilvadipine The risk or severity of adverse effects can be increased when Nilvadipine is combined with Ropivacaine. Approved Nimodipine The risk or severity of adverse effects can be increased when Nimodipine is combined with Ropivacaine. Approved Nisoldipine The risk or severity of adverse effects can be increased when Nisoldipine is combined with Ropivacaine. Approved Nitrazepam The risk or severity of adverse effects can be increased when Ropivacaine is combined with Nitrazepam. Approved Nitrendipine The risk or severity of adverse effects can be increased when Nitrendipine is combined with Ropivacaine. Approved Nitric Oxide The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Ropivacaine. Approved Nitroglycerin The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Ropivacaine. Approved, Investigational Nitroprusside The risk or severity of adverse effects can be increased when Nitroprusside is combined with Ropivacaine. Approved Nitrous oxide The risk or severity of adverse effects can be increased when Ropivacaine is combined with Nitrous oxide. Approved, Vet Approved Norflurane The risk or severity of adverse effects can be increased when Ropivacaine is combined with 1,1,1,2 Tetrafluoroethane. Investigational Normethadone The risk or severity of adverse effects can be increased when Ropivacaine is combined with Normethadone. Approved, Illicit Nortriptyline The risk or severity of adverse effects can be increased when Ropivacaine is combined with Nortriptyline. Approved Obinutuzumab The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Ropivacaine. Approved Olanzapine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Olanzapine. Approved, Investigational Olaparib The metabolism of Ropivacaine can be decreased when combined with Olaparib. Approved Olmesartan The risk or severity of adverse effects can be increased when Olmesartan is combined with Ropivacaine. Approved, Investigational Olopatadine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Olopatadine. Approved Ondansetron The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ondansetron. Approved Opium The risk or severity of adverse effects can be increased when Ropivacaine is combined with Opium. Approved, Illicit Orphenadrine Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. Approved Osanetant The risk or severity of adverse effects can be increased when Ropivacaine is combined with Osanetant. Investigational Osimertinib The serum concentration of Ropivacaine can be increased when it is combined with Osimertinib. Approved Oxazepam The risk or severity of adverse effects can be increased when Ropivacaine is combined with Oxazepam. Approved Oxethazaine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Oxetacaine. Investigational Oxprenolol The risk or severity of adverse effects can be increased when Ropivacaine is combined with Oxprenolol. Approved Oxybuprocaine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Oxybuprocaine. Approved Oxycodone The risk or severity of adverse effects can be increased when Ropivacaine is combined with Oxycodone. Approved, Illicit, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Ropivacaine is combined with Oxymorphone. Approved, Investigational, Vet Approved Paclitaxel The risk or severity of adverse effects can be increased when Paclitaxel is combined with Ropivacaine. Approved, Vet Approved Palbociclib The serum concentration of Ropivacaine can be increased when it is combined with Palbociclib. Approved Paliperidone The risk or severity of adverse effects can be increased when Ropivacaine is combined with Paliperidone. Approved Panobinostat The serum concentration of Ropivacaine can be increased when it is combined with Panobinostat. Approved, Investigational Papaverine The risk or severity of adverse effects can be increased when Papaverine is combined with Ropivacaine. Approved Paraldehyde Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. Approved Paroxetine The metabolism of Ropivacaine can be decreased when combined with Paroxetine. Approved, Investigational Peginterferon alfa-2b The serum concentration of Ropivacaine can be decreased when it is combined with Peginterferon alfa-2b. Approved Penbutolol The risk or severity of adverse effects can be increased when Penbutolol is combined with Ropivacaine. Approved, Investigational Pentazocine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Pentazocine. Approved, Vet Approved Pentobarbital The metabolism of Ropivacaine can be increased when combined with Pentobarbital. Approved, Vet Approved Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine. Approved Perazine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Perazine. Investigational Perindopril The risk or severity of adverse effects can be increased when Perindopril is combined with Ropivacaine. Approved Perospirone The risk or severity of adverse effects can be increased when Ropivacaine is combined with Perospirone. Approved Perphenazine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Perphenazine. Approved Pethidine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Pethidine. Approved Phenelzine The risk or severity of adverse effects can be increased when Phenelzine is combined with Ropivacaine. Approved Phenobarbital The metabolism of Ropivacaine can be increased when combined with Phenobarbital. Approved Phenoxybenzamine The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Ropivacaine. Approved Phenoxyethanol The risk or severity of adverse effects can be increased when Ropivacaine is combined with Phenoxyethanol. Approved Phentolamine The risk or severity of adverse effects can be increased when Phentolamine is combined with Ropivacaine. Approved Phenytoin The metabolism of Ropivacaine can be increased when combined with Phenytoin. Approved, Vet Approved Pimozide The risk or severity of adverse effects can be increased when Ropivacaine is combined with Pimozide. Approved Pindolol The risk or severity of adverse effects can be increased when Pindolol is combined with Ropivacaine. Approved Pipamperone The risk or severity of adverse effects can be increased when Ropivacaine is combined with Pipamperone. Approved Pipotiazine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Pipotiazine. Approved Piritramide The risk or severity of adverse effects can be increased when Ropivacaine is combined with Piritramide. Investigational Pizotifen The risk or severity of adverse effects can be increased when Ropivacaine is combined with Pizotifen. Approved Pomalidomide The risk or severity of adverse effects can be increased when Ropivacaine is combined with Pomalidomide. Approved Posaconazole The metabolism of Ropivacaine can be decreased when combined with Posaconazole. Approved, Investigational, Vet Approved Pramipexole Ropivacaine may increase the sedative activities of Pramipexole. Approved, Investigational Pramocaine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Pramocaine. Approved Prazepam The risk or severity of adverse effects can be increased when Ropivacaine is combined with Prazepam. Approved, Illicit Prazosin The risk or severity of adverse effects can be increased when Prazosin is combined with Ropivacaine. Approved Pregabalin The risk or severity of adverse effects can be increased when Pregabalin is combined with Ropivacaine. Approved, Illicit, Investigational Prilocaine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Prilocaine. Approved Primidone The metabolism of Ropivacaine can be increased when combined with Primidone. Approved, Vet Approved Procaine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Procaine. Approved, Investigational, Vet Approved Prochlorperazine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Prochlorperazine. Approved, Vet Approved Promazine The metabolism of Ropivacaine can be decreased when combined with Promazine. Approved, Vet Approved Promethazine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Promethazine. Approved Proparacaine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Proparacaine. Approved, Vet Approved Propofol The serum concentration of Ropivacaine can be increased when it is combined with Propofol. Approved, Investigational, Vet Approved Propoxycaine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Propoxycaine. Approved Propranolol The risk or severity of adverse effects can be increased when Propranolol is combined with Ropivacaine. Approved, Investigational Protriptyline The risk or severity of adverse effects can be increased when Ropivacaine is combined with Protriptyline. Approved PSD502 The risk or severity of adverse effects can be increased when Ropivacaine is combined with PSD502. Investigational Quazepam The serum concentration of Ropivacaine can be increased when it is combined with Quazepam. Approved, Illicit Quetiapine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Quetiapine. Approved Quinapril The risk or severity of adverse effects can be increased when Quinapril is combined with Ropivacaine. Approved, Investigational Quinidine The metabolism of Ropivacaine can be decreased when combined with Quinidine. Approved Quinine The metabolism of Ropivacaine can be decreased when combined with Quinine. Approved Raclopride The risk or severity of adverse effects can be increased when Ropivacaine is combined with Raclopride. Investigational Ramelteon The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ramelteon. Approved, Investigational Ramipril The risk or severity of adverse effects can be increased when Ramipril is combined with Ropivacaine. Approved Ranolazine The metabolism of Ropivacaine can be decreased when combined with Ranolazine. Approved, Investigational Rasagiline The risk or severity of adverse effects can be increased when Rasagiline is combined with Ropivacaine. Approved Remifentanil The risk or severity of adverse effects can be increased when Ropivacaine is combined with Remifentanil. Approved Remoxipride The risk or severity of adverse effects can be increased when Ropivacaine is combined with Remoxipride. Approved, Withdrawn Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Ropivacaine. Approved Rifabutin The metabolism of Ropivacaine can be increased when combined with Rifabutin. Approved Rifampicin The metabolism of Ropivacaine can be increased when combined with Rifampicin. Approved Rifapentine The metabolism of Ropivacaine can be increased when combined with Rifapentine. Approved Riociguat The risk or severity of adverse effects can be increased when Riociguat is combined with Ropivacaine. Approved Risperidone Ropivacaine may increase the hypotensive activities of Risperidone. Approved, Investigational Ritanserin The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ritanserin. Investigational Ritonavir The metabolism of Ropivacaine can be decreased when combined with Ritonavir. Approved, Investigational Rolapitant The metabolism of Ropivacaine can be decreased when combined with Rolapitant. Approved Romifidine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Romifidine. Vet Approved Ropinirole Ropivacaine may increase the sedative activities of Ropinirole. Approved, Investigational Rotigotine Ropivacaine may increase the sedative activities of Rotigotine. Approved Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Ropivacaine. Approved Sacubitril The risk or severity of adverse effects can be increased when Ropivacaine is combined with Sacubitril. Approved Saquinavir The metabolism of Ropivacaine can be decreased when combined with Saquinavir. Approved, Investigational Scopolamine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Scopolamine. Approved Secobarbital The risk or severity of adverse effects can be increased when Ropivacaine is combined with Secobarbital. Approved, Vet Approved Selegiline The risk or severity of adverse effects can be increased when Ropivacaine is combined with Selegiline. Approved, Investigational, Vet Approved Sepranolone The risk or severity of adverse effects can be increased when Ropivacaine is combined with Uc1010. Investigational Sertindole The risk or severity of adverse effects can be increased when Ropivacaine is combined with Sertindole. Approved, Withdrawn Sertraline The metabolism of Ropivacaine can be decreased when combined with Sertraline. Approved Sevoflurane The risk or severity of adverse effects can be increased when Ropivacaine is combined with Sevoflurane. Approved, Vet Approved Sildenafil The metabolism of Ropivacaine can be decreased when combined with Sildenafil. Approved, Investigational Siltuximab The serum concentration of Ropivacaine can be decreased when it is combined with Siltuximab. Approved Simeprevir The serum concentration of Ropivacaine can be increased when it is combined with Simeprevir. Approved Sodium Nitrite The risk or severity of adverse effects can be increased when Ropivacaine is combined with Sodium Nitrite. Approved Sodium oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine. Approved Sorafenib The metabolism of Ropivacaine can be decreased when combined with Sorafenib. Approved, Investigational Sotalol The risk or severity of adverse effects can be increased when Sotalol is combined with Ropivacaine. Approved Spironolactone The risk or severity of adverse effects can be increased when Spironolactone is combined with Ropivacaine. Approved St. John's Wort The serum concentration of Ropivacaine can be decreased when it is combined with St. John's Wort. Nutraceutical Stiripentol The serum concentration of Ropivacaine can be increased when it is combined with Stiripentol. Approved Streptokinase The risk or severity of adverse effects can be increased when Ropivacaine is combined with Streptokinase. Approved Sufentanil The risk or severity of adverse effects can be increased when Ropivacaine is combined with Sufentanil. Approved, Investigational Sulfisoxazole The metabolism of Ropivacaine can be decreased when combined with Sulfisoxazole. Approved, Vet Approved Sulpiride The risk or severity of adverse effects can be increased when Ropivacaine is combined with Sulpiride. Approved Suvorexant Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. Approved Tamsulosin The risk or severity of adverse effects can be increased when Ropivacaine is combined with Tamsulosin. Approved, Investigational Tandospirone The risk or severity of adverse effects can be increased when Ropivacaine is combined with Tandospirone. Investigational Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine. Approved Tasimelteon The risk or severity of adverse effects can be increased when Ropivacaine is combined with Tasimelteon. Approved Technetium Tc-99m tilmanocept Ropivacaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent. Approved Telaprevir The metabolism of Ropivacaine can be decreased when combined with Telaprevir. Withdrawn Telithromycin The metabolism of Ropivacaine can be decreased when combined with Telithromycin. Approved Telmisartan The risk or severity of adverse effects can be increased when Telmisartan is combined with Ropivacaine. Approved, Investigational Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Ropivacaine. Approved Tenofovir disoproxil The metabolism of Ropivacaine can be decreased when combined with Tenofovir. Approved, Investigational Terazosin The risk or severity of adverse effects can be increased when Terazosin is combined with Ropivacaine. Approved Terbinafine The metabolism of Ropivacaine can be decreased when combined with Terbinafine. Approved, Investigational, Vet Approved Teriflunomide The serum concentration of Ropivacaine can be decreased when it is combined with Teriflunomide. Approved Tetrabenazine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Tetrabenazine. Approved Tetracaine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Tetracaine. Approved, Vet Approved Tetrodotoxin The risk or severity of adverse effects can be increased when Ropivacaine is combined with Tetrodotoxin. Investigational Thalidomide Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. Approved, Investigational, Withdrawn Theophylline The metabolism of Ropivacaine can be decreased when combined with Theophylline. Approved Thiamylal The risk or severity of adverse effects can be increased when Ropivacaine is combined with Thiamylal. Approved, Vet Approved Thiopental The risk or severity of adverse effects can be increased when Ropivacaine is combined with Thiopental. Approved, Vet Approved Thioridazine The metabolism of Ropivacaine can be decreased when combined with Thioridazine. Withdrawn Thiotepa The metabolism of Ropivacaine can be decreased when combined with Thiotepa. Approved Thiothixene The risk or severity of adverse effects can be increased when Ropivacaine is combined with Thiothixene. Approved Tiagabine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Tiagabine. Approved Tiapride The risk or severity of adverse effects can be increased when Ropivacaine is combined with Tiapride. Approved, Investigational Ticlopidine The metabolism of Ropivacaine can be decreased when combined with Ticlopidine. Approved Tiletamine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Tiletamine. Vet Approved Timolol The risk or severity of adverse effects can be increased when Timolol is combined with Ropivacaine. Approved Tipranavir The metabolism of Ropivacaine can be decreased when combined with Tipranavir. Approved, Investigational Tizanidine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Tizanidine. Approved Tocilizumab The serum concentration of Ropivacaine can be decreased when it is combined with Tocilizumab. Approved Tolazoline The risk or severity of adverse effects can be increased when Ropivacaine is combined with Tolazoline. Approved, Vet Approved Tolcapone The risk or severity of adverse effects can be increased when Ropivacaine is combined with Tolcapone. Approved, Withdrawn Topiramate The risk or severity of adverse effects can be increased when Ropivacaine is combined with Topiramate. Approved Torasemide The risk or severity of adverse effects can be increased when Torasemide is combined with Ropivacaine. Approved Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Ropivacaine. Approved, Investigational Trandolapril The risk or severity of adverse effects can be increased when Trandolapril is combined with Ropivacaine. Approved Trans-2-Phenylcyclopropylamine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Trans-2-Phenylcyclopropylamine. Experimental Tranylcypromine The metabolism of Ropivacaine can be decreased when combined with Tranylcypromine. Approved Trazodone The risk or severity of adverse effects can be increased when Ropivacaine is combined with Trazodone. Approved, Investigational Tretinoin The risk or severity of adverse effects can be increased when Ropivacaine is combined with Tretinoin. Approved, Investigational, Nutraceutical Triamterene The risk or severity of adverse effects can be increased when Triamterene is combined with Ropivacaine. Approved Triazolam The risk or severity of adverse effects can be increased when Ropivacaine is combined with Triazolam. Approved Trifluoperazine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Trifluoperazine. Approved Triflupromazine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Triflupromazine. Approved, Vet Approved Trimipramine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Trimipramine. Approved Triprolidine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Triprolidine. Approved Valproic Acid The risk or severity of adverse effects can be increased when Ropivacaine is combined with Valproic Acid. Approved, Investigational Valsartan The risk or severity of adverse effects can be increased when Valsartan is combined with Ropivacaine. Approved, Investigational Vemurafenib The serum concentration of Ropivacaine can be increased when it is combined with Vemurafenib. Approved Venlafaxine The metabolism of Ropivacaine can be decreased when combined with Venlafaxine. Approved Verapamil The metabolism of Ropivacaine can be decreased when combined with Verapamil. Approved Vigabatrin The risk or severity of adverse effects can be increased when Ropivacaine is combined with Vigabatrin. Approved Voriconazole The metabolism of Ropivacaine can be decreased when combined with Voriconazole. Approved, Investigational Vortioxetine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Vortioxetine. Approved Xylazine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Xylazine. Vet Approved Zaleplon The risk or severity of adverse effects can be increased when Ropivacaine is combined with Zaleplon. Approved, Illicit, Investigational Ziconotide The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ziconotide. Approved Zimelidine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Zimelidine. Withdrawn Ziprasidone The metabolism of Ropivacaine can be decreased when combined with Ziprasidone. Approved Zolazepam The risk or severity of adverse effects can be increased when Ropivacaine is combined with Zolazepam. Vet Approved Zolpidem Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Approved Zonisamide The risk or severity of adverse effects can be increased when Ropivacaine is combined with Zonisamide. Approved, Investigational Zopiclone The risk or severity of adverse effects can be increased when Ropivacaine is combined with Zopiclone. Approved Zotepine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Zotepine. Approved Zuclopenthixol The risk or severity of adverse effects can be increased when Ropivacaine is combined with Zuclopenthixol. Approved, Investigational - Food Interactions
- Not Available
References
- Synthesis Reference
Peter Jaksch, "Process for the preparation of ropivacaine hydrochloride monohydrate." U.S. Patent US5959112, issued February, 1970.
US5959112- General References
- Weinberg G, Ripper R, Feinstein DL, Hoffman W: Lipid emulsion infusion rescues dogs from bupivacaine-induced cardiac toxicity. Reg Anesth Pain Med. 2003 May-Jun;28(3):198-202. [PubMed:12772136 ]
- Picard J, Meek T: Lipid emulsion to treat overdose of local anaesthetic: the gift of the glob. Anaesthesia. 2006 Feb;61(2):107-9. [PubMed:16430560 ]
- Rosenblatt MA, Abel M, Fischer GW, Itzkovich CJ, Eisenkraft JB: Successful use of a 20% lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiac arrest. Anesthesiology. 2006 Jul;105(1):217-8. [PubMed:16810015 ]
- External Links
- Human Metabolome Database
- HMDB14441
- KEGG Compound
- C07532
- ChemSpider
- 153165
- ChEBI
- 8890
- ChEMBL
- CHEMBL1077896
- Therapeutic Targets Database
- DAP001230
- PharmGKB
- PA451271
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Ropivacaine
- ATC Codes
- N01BB09 — Ropivacaine
- AHFS Codes
- 72:00.00
- PDB Entries
- Not Available
- FDA label
- Download (274 KB)
- MSDS
- Download (57 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- App pharmaceuticals llc
- Packagers
- APP Pharmaceuticals
- Astra Pharma Inc.
- AstraZeneca Inc.
- Pharmakon
- Pharmedium
- Dosage forms
Form Route Strength Injection, solution Epidural; Infiltration 2 mg/mL Solution Epidural 2 mg Solution Epidural; Infiltration 10 mg Liquid Parenteral 7.5 mg Injection, solution Epidural 10 mg/mL Injection, solution Epidural; Infiltration; Perineural 2 mg/mL Injection, solution Epidural; Infiltration; Perineural 5 mg/mL Injection, solution Epidural; Perineural 7.5 mg/mL Injection, solution Parenteral 10 mg/mL Injection, solution Parenteral 5 mg/mL Solution Epidural; Infiltration 2 mg Solution Epidural 10 mg Solution Epidural 7.5 mg Solution Epidural; Infiltration 5 mg Solution Infiltration 2 mg - Prices
Unit description Cost Unit Ropivacaine hcl-ns 0.5% 1.84USD ml Ropivacaine hcl 0.2% on-q pump 0.99USD ml Naropin 10 mg/ml ampule 0.97USD ml Ropivacaine hcl-ns 0.3% 0.9USD ml Ropivacaine-ns 0.1% on-q pump 0.71USD ml Naropin 7.5 mg/ml ampule 0.62USD ml Naropin 5 mg/ml vial 0.58USD ml Ropivacaine hcl-ns 0.15% 0.51USD ml Ropivacaine hcl-ns 0.125% 0.48USD ml Naropin 5 mg/ml ampule 0.46USD ml Naropin 2 mg/ml ampule 0.44USD ml Ropivacaine hcl-ns 0.1% 0.39USD ml Ropivacaine hcl-ns 0.25% 0.34USD ml Ropivacaine hcl-ns 0.2% 0.29USD ml Naropin 2 mg/ml infusion btl 0.23USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US5670524 No 1994-05-26 2014-05-26 US US4870086 No 1993-09-24 2010-09-24 US CA2165446 No 2005-07-05 2014-05-26 Canada CA1337549 No 1995-11-14 2012-11-14 Canada US8118802 No 2003-05-18 2023-05-18 US US7857802 No 2006-11-28 2026-11-28 US US7828787 No 2005-10-18 2025-10-18 US US8162915 No 2004-05-23 2024-05-23 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source water solubility 57.6 mg/L Not Available logP 2.90 HANSCH,C ET AL. (1995) pKa 8.07 Not Available - Predicted Properties
Property Value Source Water Solubility 0.253 mg/mL ALOGPS logP 2.91 ALOGPS logP 4.07 ChemAxon logS -3 ALOGPS pKa (Strongest Acidic) 13.62 ChemAxon pKa (Strongest Basic) 7.82 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 32.34 Å2 ChemAxon Rotatable Bond Count 4 ChemAxon Refractivity 85.59 m3·mol-1 ChemAxon Polarizability 32.67 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9705 Blood Brain Barrier + 0.9377 Caco-2 permeable + 0.5912 P-glycoprotein substrate Substrate 0.8037 P-glycoprotein inhibitor I Inhibitor 0.8768 P-glycoprotein inhibitor II Non-inhibitor 0.6339 Renal organic cation transporter Non-inhibitor 0.6611 CYP450 2C9 substrate Non-substrate 0.819 CYP450 2D6 substrate Substrate 0.8919 CYP450 3A4 substrate Substrate 0.723 CYP450 1A2 substrate Non-inhibitor 0.5499 CYP450 2C9 inhibitor Non-inhibitor 0.9246 CYP450 2D6 inhibitor Inhibitor 0.8821 CYP450 2C19 inhibitor Non-inhibitor 0.8773 CYP450 3A4 inhibitor Non-inhibitor 0.5902 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.6116 Ames test Non AMES toxic 0.8507 Carcinogenicity Non-carcinogens 0.8763 Biodegradation Not ready biodegradable 0.9783 Rat acute toxicity 2.2964 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8009 hERG inhibition (predictor II) Inhibitor 0.8438
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted LC-MS/MS Spectrum - 10V, Positive Predicted LC-MS/MS Not Available Predicted LC-MS/MS Spectrum - 20V, Positive Predicted LC-MS/MS Not Available Predicted LC-MS/MS Spectrum - 40V, Positive Predicted LC-MS/MS Not Available Predicted LC-MS/MS Spectrum - 10V, Negative Predicted LC-MS/MS Not Available Predicted LC-MS/MS Spectrum - 20V, Negative Predicted LC-MS/MS Not Available Predicted LC-MS/MS Spectrum - 40V, Negative Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of chemical entities known as alpha amino acid amides. These are amide derivatives of alpha amino acids.
- Kingdom
- Chemical entities
- Super Class
- Organic compounds
- Class
- Organic acids and derivatives
- Sub Class
- Carboxylic acids and derivatives
- Direct Parent
- Alpha amino acid amides
- Alternative Parents
- Piperidinecarboxamides / Anilides / m-Xylenes / N-arylamides / Trialkylamines / Secondary carboxylic acid amides / Azacyclic compounds / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives show 1 more
- Substituents
- Alpha-amino acid amide / 2-piperidinecarboxamide / Piperidinecarboxamide / Anilide / M-xylene / Xylene / N-arylamide / Monocyclic benzene moiety / Benzenoid / Piperidine show 16 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- piperidinecarboxamide, ropivacaine (CHEBI:8890 )
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Voltage-gated sodium channel activity
- Specific Function
- Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference acro...
- Gene Name
- SCN10A
- Uniprot ID
- Q9Y5Y9
- Uniprot Name
- Sodium channel protein type 10 subunit alpha
- Molecular Weight
- 220623.605 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
- Liu BG, Zhuang XL, Li ST, Xu GH: The effects of ropivacaine on sodium currents in dorsal horn neurons of neonatal rats. Anesth Analg. 2000 May;90(5):1034-8. [PubMed:10781449 ]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A2
- Uniprot ID
- P05177
- Uniprot Name
- Cytochrome P450 1A2
- Molecular Weight
- 58293.76 Da
References
- Arlander E, Ekstrom G, Alm C, Carrillo JA, Bielenstein M, Bottiger Y, Bertilsson L, Gustafsson LL: Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. Clin Pharmacol Ther. 1998 Nov;64(5):484-91. [PubMed:9834040 ]
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2B6
- Uniprot ID
- P20813
- Uniprot Name
- Cytochrome P450 2B6
- Molecular Weight
- 56277.81 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
- Gene Name
- CYP2D6
- Uniprot ID
- P10635
- Uniprot Name
- Cytochrome P450 2D6
- Molecular Weight
- 55768.94 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Drug created on June 13, 2005 07:24 / Updated on September 26, 2017 08:23